Aastrom announces first patients treated in ixCELL-DCM clinical study of ixmyelocel-T Aastrom Biosciences announced that the first patients were treated in the ixCELL-DCM Phase 2b clinical trial. This study is evaluating the safety and efficacy of ixmyelocel-T compared to placebo in patients with advanced heart failure due to ischemic dilated cardiomyopathy. Aastrom has received U.S. orphan drug designation for the use of ixmyelocel-T in patients with DCM.
News For ASTM From The Last 14 Days
Check below for free stories on ASTM the last two weeks.
Aastrom announces definitive agreement to acquire Sanofi's CTRM business Aastrom Biosciences (ASTM) announced that it has entered into a definitive agreement to acquire Sanofi's (SNY) Cell Therapy and Regenerative Medicine, or CTRM, business for a purchase price of $6.5M, with $4M payable in cash at closing and $2.5M payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Through the CTRM acquisition, Aastrom is acquiring global commercial rights to three marketed autologous cell therapy products. Aastrom will also acquire global manufacturing and production centers located in the United States and Denmark.